NHP Intracerebral (ICM) Injection| Prisys Biotech
Precision Intracerebral (ICM) Injection Services in NHPs
Intracerebral (ICM) injection is a highly specialized administration route that enables direct delivery of therapeutics into defined brain regions, bypassing the blood–brain barrier and achieving maximal local exposure. This approach is increasingly critical for the development of gene therapies, cell therapies, and targeted biologics requiring precise engagement of specific neural structures.
Prisys Biotechnologies provides stereotaxic, image-guided intracerebral injection services in non-human primates (NHPs), supporting translational CNS research from early feasibility to advanced preclinical studies. By utilizing our advanced non-human primates platform, researchers can achieve unprecedented accuracy in localized drug delivery.
Service Overview
Prisys offers a fully integrated ICM platform designed for targeted delivery into specific brain regions, such as the putamen, hippocampus, cortex, and thalamus. This service is particularly suited for programs requiring high local drug concentration, site-specific expression, or localized therapeutic intervention. Our core capabilities include:
- Targeted Delivery: Support for gene therapy, viral vectors, and biologics into functionally relevant brain areas.
- Stereotaxic Surgery: Precise intracranial procedures performed under advanced imaging guidance.
- Safety Evaluation: Comprehensive post-procedural functional and safety assessments to ensure clinical relevance.
Key Technical Capabilities
MRI-Guided Stereotaxic Targeting
Accurate localization is fundamental to ICM studies. Prisys integrates MRI imaging with stereotaxic systems to enable three-dimensional brain targeting at sub-millimetric precision, ensuring reliable and reproducible delivery into predefined anatomical regions.
Flexible Brain Region Targeting
Injection coordinates are customized based on study objectives, allowing precise targeting of functionally relevant brain areas. This flexibility supports diverse applications, including neurodegenerative disease models, movement disorders, and focal CNS pathologies. For broader neurological applications, we also offer intracerebroventricular (ICV) injection as an alternative route.
Controlled Micro-Volume Delivery
Using fine cannula systems and controlled infusion parameters, Prisys ensures accurate dosing and minimized tissue disruption, which is essential for sensitive CNS studies and translational consistency.
Integrated Safety and Functional Assessment
ICM studies at Prisys are supported by comprehensive evaluation frameworks, including clinical monitoring, histopathological evaluation of injection sites, and behavioral analysis using our AI-based NHP Behavior Analysis System. This is critical when evaluating models such as the MPTP-induced Parkinson's disease (PD) model.
Translational Value for CNS Drug Development
ICM administration provides a unique advantage in CNS drug development by enabling direct target engagement within specific brain structures. This results in significantly higher local drug or gene expression levels compared to systemic or CSF-based routes, while reducing systemic exposure and off-target effects. This approach is particularly valuable for rare neurological disorders and precision neuromodulation strategies.
FAQ
Q: When is intracerebral (ICM) injection preferred over IT or ICV routes?
A: ICM is preferred when precise, localized delivery to a specific brain region is required, particularly for gene therapies or conditions where target engagement must be restricted to defined anatomical structures.
Q: What types of therapeutics are best suited for ICM administration?
A: ICM is widely used for AAV-based gene therapies, cell therapies, and biologics that require high local concentration or targeted expression within the brain.
Q: How does Prisys ensure accuracy and safety in ICM procedures?
A: Prisys combines MRI-guided stereotaxic systems, experienced surgical teams, controlled infusion technologies, and comprehensive post-procedure monitoring to ensure high precision and safety.
References
1. Bankiewicz, K. S., et al. (2016). Convection-enhanced delivery of AAV2-GDNF in non-human primates. Human Gene Therapy.
2. Samaranch, L., et al. (2019). Direct Intracerebral Administration of AAV Vectors: Clinical Applications and Preclinical Considerations. Gene Therapy Journal.
Hot Tags: NHP Intracerebral (ICM) Injection| Prisys Biotech, research, study, monkey, gene therapy, in vivo pharmacokinetics, ADME, Non human primate PK, Pharmacokinetics, PK PD ADME, Pharmacodynamics
You Might Also Like
Send Inquiry